As Korea rapidly emerges as a global hub for drug discovery innovation, this forum will allow you to explore best-in-class platforms for next-generation modalities by integrating AI for smarter, faster, and de-risked drug discovery.
With modality-agnostic content split 50:50 between biologics and small molecule therapies, here’s a sneak peek of the pan-modality insights case studies utilizing structural biology, biophysics, and computational workflows to unlock in December:
ADCs & Antibody Therapeutics
Utilizing TuneLab AI Models to Access Lilly-Trained Resources & Overcome Challenges in Drug Discovery
Vanessa Braunstein, Senior Director, TuneLab AI Drug Discovery Platform Ecosystem Growth, Eli Lilly
Utilizing Spatial Biology & PK/PD Data to Optimize Target Discovery, Target-Linker Pairing & Payload Selection for Innovative ADC Discovery
Daeseung Lee, Co-Founder & Chief Executive Officer, Portrai
Induced Proximity & Molecular Glues
AI4GLUE: Closing the Design–Experiment Loop for Predictive Discovery of Molecular Glues
Chunhui Xu, Lead, AI4Glue Platform, Degron Therapeutics
Self-Driving Drug Discovery: Leveraging Autonomous Research AI to Orchestrate Foundation Models for Molecular Glue Degrader Discovery
Jaewoo Kang, Founder & Chief Executive Officer, AIGEN Sciences
Peptides & Cancer Vaccines
Navigating Data Generation, Standardization & Iterative Feedback to Develop an AI-Driven Platform to Accelerate Discovery of Novel Peptide Therapies
Shan Chen, Senior Director, AIDD, Innovent Biologics
Exploring Applications of In Silico Screening to Enable Faster & More Precise Antigen Epitope Discovery for Cancer Vaccine Therapies
Wonil Kim, Chief Scientific Officer, Aston Sci
Explore the Agenda
Hear the latest discovery innovations taking place within South Korea as well as perspectives from global experts.
Partner With Us
Position yourself to ensure your company is seen as the go-to discovery service provider for Korean drug developers.
Join Biopharma Experts
Be part of the technical and strategic conversations with 100+ drug discovery enthusiasts and decision makers.